TYSABRI (natalizumab): Reviews and patient testimonials


Medication indications

TYSABRI 300 mg concentrate for solution for infusion

TYSABRI is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:

• Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)


• Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Route of administration: Injectable
Molecule: natalizumab

Patients' opinions on TYSABRI

In brief

General satisfaction level: 9.25/10 Learn more

Treatment's effectiveness: 9.50/10 Learn more

Ease of use: 8.00/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 1.50/10 Learn more

Improvement in the quality of life: 8.25/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

on 09/04/2020

I went straight onto Tysabri, due to the aggression of the MS & after a couple of sessions of steroids that only helped whilst they were in my system and then a plasma exchange which was the start of my 'recovery'...ie a return to some form of my old normal. I have been on it since July 2019 and since then regained my mobility & life, as was best described as paralysed prior to tysabri due to the relapses. I tell my people its time to go renew my blood glue when im off for infusions, as that is the best way ive found to describe what it is when asked.

Your message

on 26/02/2019

First break for years.

Your message

Conditions related to this medication

Fact sheet

Multiple sclerosis

See the fact sheet